HOME >> BIOLOGY >> NEWS
Sidebar: new trial should lead to better understanding of why exercise is an effective treatment for depression

DURHAM, N.C. -- The Duke University Medical Center researchers who found evidence that exercise can be an effective treatment for major depression are embarking on a larger trial they believe will answer some of the remaining questions posed by their earlier results.

The new trial, which is being funded by a $3 million grant from the National Institute of Mental Health, is designed to further refine which depressed patients can benefit from exercise and determine why exercise appears to be effective. Additionally, the study will measure the effect of exercise on a phenomenon known as vascular depression, a form of depression that appears linked to actual abnormalities in blood vessels of the brain, and not brain chemical imbalances. The previous Duke studies, led by psychologist James Blumenthal, found that exercise was just as effective as the most common anti-depressive medication in reducing the symptoms of major depression.

"This new trial is intended to answer some of the whys' posed by those original studies," Blumenthal explained. "We are very interested in evaluating behavioral, non-pharmacologic approaches to treating depression. Because up to one-third of depressed patients may not respond to drug therapy, and those who do take drugs may complain of side effects, it is important to find other approaches."

Over the next five years, the researchers plan to enroll 216 volunteers, half of whom will be assigned randomly to the drug arm of the trial and half to the exercise arm. The drug to be used is sertraline (trade name Zoloft), a member of a class of commonly used anti-depressants known as selective serotonin reuptake inhibitors, and the same drug used in the earlier trials.

Unlike the earlier trials, the new trial will have a placebo, or ineffective sugar pill, arm. Also unlike the earlier trials, the exercise arm will be divided as well -- half of the patients will do thei
'"/>

Contact: Richard Merritt
merri006@mc.duke.edu
919-684-4148
Duke University Medical Center
20-Sep-2000


Page: 1 2 3

Related biology news :

1. Phase II trials of second-generation antisense cancer drug planned following successful early study
2. Innovative ceramic-on-metal hip replacements to undergo clinical trials
3. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
4. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
5. Pharmacogenomics could replace trial-and-error with science from the human genome
6. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
7. Small trial shows daclizumab add-on therapy improves MS outcome
8. Tigecycline - antibiotic evaluated in surveillance trial
9. OneWorld Health completes enrollment, treatment in Phase III India trial
10. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
11. First large-scale trial of genetically personalised treatment for breast cancer to start soon

Post Your Comments:
(Date:11/4/2014)... , November 4, 2014   ... vertical market growth   Fuel3D , a ... closed a funding round totaling $6.4 million (£4 million). This ... funding secured earlier this year and paves the way for ... 2015. The funding round was led by Chimera ...
(Date:11/4/2014)...   Neurotechnology , a provider of high-precision ... version of its fingerprint matching algorithm has achieved ... evaluation organized by NIST. The MINEX test measures ... 378 fingerprint standard template format. MINEX compliance is ... the United States and ...
(Date:11/3/2014)... study published in this month,s Proceedings ... activity of a recently discovered communication molecule of the ... been known to limit inflammation and the current study ... inhibits the ability of the immune system to recognize ... underlies IL-37,s effect on the immune system now allows ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
(Date:11/24/2014)... , November 24, 2014 ... Workflow, honored for dynamic leadership skills, business acumen ... technical and medical information products and services, congratulates ... for Clinical Reference and Workflow, Elsevier Clinical Solutions, for ... Worth Watching ® Awards issue of Profiles ...
(Date:11/22/2014)... London (PRWEB) November 21, 2014 Two new ... explore what comes next for ALS research and how the ... , After the Ice Bucket Challenge: Where Does the ALS ... Tuesday, 2 December 2014, Time: 1:30pm ET, ... Join expert speaker Dr. Merit Cudkowicz, Julianne Dorn Professor of ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 Prominent ... investors will gather on December 3rd at Genetic ... Conferences series. GeneticRx will take place at the ... School and will discuss the present and future ... exon skipping, and gene editing—as well as the ...
(Date:11/22/2014)... RURO, Inc., a leading LIMS, RFID ... version 5.1.4. , RURO’s deployment teams have been ... in RURO’s 8 year history. Many deployments have ... version 5.1.4 is the perfect example – the ... , Limfinity® 5.1.4 release highlights – more than ...
Breaking Biology Technology:Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2RURO Announces Limfinity® version 5.1.4 2
Cached News: